ECYT - To me it seems clear that they initially plan on running just a single trial on FR++ patients ie PROCEED. Financially that may be a sound move since the results may be resoundingly good and ECYT may not need to run an additional trial though if the FDA asks for a 2nd one its going to take longer for EC145 to be commercialized in the US. However if the trials are small then they shouldn't last too long.
Market Data 
Markets 
AI
